Oxford BioTherapeutics and Boehringer Ingelheim Corporation Enter Collaboration to Discover Novel Antibody Targets in Cancer
4/29/2013 9:49:15 AM
More...
|
Menarini, Oxford BioTherapeutics Ink $1 Billion Cancer Pact; Partnership Will Develop Five Antibody-Based Anticancer Drugs
10/29/2012 9:50:05 AM
More...
|
Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
5/2/2012 10:35:47 AM
More...
|
Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
1/11/2012 2:12:28 PM
More...
|
Seattle Genetics, Inc. (SGEN) and Oxford BioTherapeutics to Collaborate on Antibody-Drug Conjugates for Cancer
9/13/2011 10:37:42 AM
More...
|
CMC Biologics Licenses Its CHEF1(R) Expression System to Oxford BioTherapeutics
9/7/2011 11:00:57 AM
More...
|
Oxford BioTherapeutics Licenses BioWa's POTELLIGENT(R) Technology for the Research and Development of its Therapeutic Antibodies in Cancer
4/6/2011 7:40:13 AM
More...
|
Oxford BioTherapeutics Appoints Michael Moore as Chairman
12/9/2009 11:14:41 AM
More...
|